CA3060909A1 - Procede d'encapsulation de cannabinoides dans des supports de phospholipides - Google Patents

Procede d'encapsulation de cannabinoides dans des supports de phospholipides Download PDF

Info

Publication number: CA3060909A1
Authority: CA; Canada
Prior art keywords: cannabis; cbd; solution; derived; sativa
Prior art date: 2018-09-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CA3060909A

Other languages

English (en)

Inventor

Tanya Rhodes

Deborah Duffey

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Nuvessl Inc

Original Assignee

Nuvessl Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-09-06

Filing date

2019-11-05

Publication date

2020-03-06

2019-09-04 Priority claimed from US16/560,470 external-priority patent/US11020355B2/en

2019-11-05 Application filed by Nuvessl Inc filed Critical Nuvessl Inc

2020-03-06 Publication of CA3060909A1 publication Critical patent/CA3060909A1/fr

Status Pending legal-status Critical Current

Links

150000003904 phospholipids Chemical class 0.000 title claims abstract description 149
238000000034 method Methods 0.000 title claims abstract description 45
229930003827 cannabinoid Natural products 0.000 title abstract description 36
239000003557 cannabinoid Substances 0.000 title abstract description 36
229940065144 cannabinoids Drugs 0.000 title abstract description 29
239000000969 carrier Substances 0.000 title description 3
239000000126 substance Substances 0.000 claims abstract description 147
244000025254 Cannabis sativa Species 0.000 claims abstract description 79
235000008697 Cannabis sativa Nutrition 0.000 claims abstract description 62
241000218236 Cannabis Species 0.000 claims abstract 39
QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 294
QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 289
ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 289
229950011318 cannabidiol Drugs 0.000 claims description 289
PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 289
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 242
210000003296 saliva Anatomy 0.000 claims description 113
CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 101
CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical group C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 101
229960004242 dronabinol Drugs 0.000 claims description 101
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 66
150000003505 terpenes Chemical class 0.000 claims description 22
235000007586 terpenes Nutrition 0.000 claims description 22
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 21
239000000419 plant extract Substances 0.000 claims description 21
229930003935 flavonoid Natural products 0.000 claims description 17
150000002215 flavonoids Chemical class 0.000 claims description 17
235000017173 flavonoids Nutrition 0.000 claims description 17
238000002156 mixing Methods 0.000 claims description 16
238000007865 diluting Methods 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 8
239000000284 extract Substances 0.000 abstract description 39
239000000203 mixture Substances 0.000 abstract description 38
150000001875 compounds Chemical class 0.000 abstract description 32
230000037317 transdermal delivery Effects 0.000 abstract description 9
238000009472 formulation Methods 0.000 abstract description 4
240000004308 marijuana Species 0.000 description 257
239000000243 solution Substances 0.000 description 61
238000002360 preparation method Methods 0.000 description 46
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 26
239000003125 aqueous solvent Substances 0.000 description 25
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 20
238000005538 encapsulation Methods 0.000 description 17
235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 15
235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 15
238000000605 extraction Methods 0.000 description 15
235000009120 camo Nutrition 0.000 description 14
235000005607 chanvre indien Nutrition 0.000 description 14
239000011487 hemp Substances 0.000 description 14
210000002966 serum Anatomy 0.000 description 14
229910002092 carbon dioxide Inorganic materials 0.000 description 13
239000000463 material Substances 0.000 description 13
239000002904 solvent Substances 0.000 description 12
239000001273 butane Substances 0.000 description 11
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 11
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 11
241000196324 Embryophyta Species 0.000 description 10
239000000499 gel Substances 0.000 description 10
239000003921 oil Substances 0.000 description 10
235000019198 oils Nutrition 0.000 description 10
239000001294 propane Substances 0.000 description 10
239000007921 spray Substances 0.000 description 10
239000003795 chemical substances by application Substances 0.000 description 8
235000009508 confectionery Nutrition 0.000 description 8
238000010790 dilution Methods 0.000 description 8
239000012895 dilution Substances 0.000 description 8
230000000694 effects Effects 0.000 description 8
150000002632 lipids Chemical class 0.000 description 8
229940079593 drug Drugs 0.000 description 7
210000004877 mucosa Anatomy 0.000 description 7
244000062730 Melissa officinalis Species 0.000 description 6
235000010654 Melissa officinalis Nutrition 0.000 description 6
239000006071 cream Substances 0.000 description 6
239000003814 drug Substances 0.000 description 6
239000000865 liniment Substances 0.000 description 6
239000006210 lotion Substances 0.000 description 6
210000002200 mouth mucosa Anatomy 0.000 description 6
239000002674 ointment Substances 0.000 description 6
239000004006 olive oil Substances 0.000 description 6
235000008390 olive oil Nutrition 0.000 description 6
230000008569 process Effects 0.000 description 6
230000000391 smoking effect Effects 0.000 description 6
239000001993 wax Substances 0.000 description 6
244000198134 Agave sisalana Species 0.000 description 5
235000011624 Agave sisalana Nutrition 0.000 description 5
210000002615 epidermis Anatomy 0.000 description 5
239000007788 liquid Substances 0.000 description 5
210000000214 mouth Anatomy 0.000 description 5
239000003960 organic solvent Substances 0.000 description 5
AAXZFUQLLRMVOG-UHFFFAOYSA-N 2-methyl-2-(4-methylpent-3-enyl)-7-propylchromen-5-ol Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCC)=CC(O)=C21 AAXZFUQLLRMVOG-UHFFFAOYSA-N 0.000 description 4
239000000443 aerosol Substances 0.000 description 4
239000006196 drop Substances 0.000 description 4
239000007937 lozenge Substances 0.000 description 4
230000000873 masking effect Effects 0.000 description 4
239000006072 paste Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
230000008016 vaporization Effects 0.000 description 4
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
230000002411 adverse Effects 0.000 description 3
150000001298 alcohols Chemical class 0.000 description 3
239000013078 crystal Substances 0.000 description 3
230000036541 health Effects 0.000 description 3
239000000787 lecithin Substances 0.000 description 3
235000010445 lecithin Nutrition 0.000 description 3
229940067606 lecithin Drugs 0.000 description 3
239000008213 purified water Substances 0.000 description 3
239000000779 smoke Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
RBEAVAMWZAJWOI-MTOHEIAKSA-N (5as,6s,9r,9ar)-6-methyl-3-pentyl-9-prop-1-en-2-yl-7,8,9,9a-tetrahydro-5ah-dibenzofuran-1,6-diol Chemical compound C1=2C(O)=CC(CCCCC)=CC=2O[C@H]2[C@@H]1[C@H](C(C)=C)CC[C@]2(C)O RBEAVAMWZAJWOI-MTOHEIAKSA-N 0.000 description 2
ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 description 2
IXJXRDCCQRZSDV-GCKMJXCFSA-N (6ar,9r,10as)-6,6,9-trimethyl-3-pentyl-6a,7,8,9,10,10a-hexahydro-6h-1,9-epoxybenzo[c]chromene Chemical compound C1C[C@@H](C(O2)(C)C)[C@@H]3C[C@]1(C)OC1=C3C2=CC(CCCCC)=C1 IXJXRDCCQRZSDV-GCKMJXCFSA-N 0.000 description 2
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
YJYIDZLGVYOPGU-XNTDXEJSSA-N 2-[(2e)-3,7-dimethylocta-2,6-dienyl]-5-propylbenzene-1,3-diol Chemical compound CCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-XNTDXEJSSA-N 0.000 description 2
-1 CBD Natural products 0.000 description 2
206010058019 Cancer Pain Diseases 0.000 description 2
WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 description 2
KASVLYINZPAMNS-UHFFFAOYSA-N Cannabigerol monomethylether Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(OC)=C1 KASVLYINZPAMNS-UHFFFAOYSA-N 0.000 description 2
UCONUSSAWGCZMV-HZPDHXFCSA-N Delta(9)-tetrahydrocannabinolic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCCCC)C(C(O)=O)=C1O UCONUSSAWGCZMV-HZPDHXFCSA-N 0.000 description 2
ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
210000005178 buccal mucosa Anatomy 0.000 description 2
WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 description 2
QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 description 2
QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 description 2
YJYIDZLGVYOPGU-UHFFFAOYSA-N cannabigeroldivarin Natural products CCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-UHFFFAOYSA-N 0.000 description 2
229910017052 cobalt Inorganic materials 0.000 description 2
239000010941 cobalt Substances 0.000 description 2
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
210000003128 head Anatomy 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
150000003905 phosphatidylinositols Chemical class 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
230000001766 physiological effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000010926 purge Methods 0.000 description 2
238000000638 solvent extraction Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000003815 supercritical carbon dioxide extraction Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 2
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
241000218235 Cannabaceae Species 0.000 description 1
UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 description 1
REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 description 1
VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
IGHTZQUIFGUJTG-QSMXQIJUSA-N O1C2=CC(CCCCC)=CC(O)=C2[C@H]2C(C)(C)[C@@H]3[C@H]2[C@@]1(C)CC3 Chemical compound O1C2=CC(CCCCC)=CC(O)=C2[C@H]2C(C)(C)[C@@H]3[C@H]2[C@@]1(C)CC3 IGHTZQUIFGUJTG-QSMXQIJUSA-N 0.000 description 1
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
150000001491 aromatic compounds Chemical class 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
SVTKBAIRFMXQQF-UHFFFAOYSA-N cannabivarin Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCC)C=C3OC(C)(C)C2=C1 SVTKBAIRFMXQQF-UHFFFAOYSA-N 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
AZHSSKPUVBVXLK-UHFFFAOYSA-N ethane-1,1-diol Chemical compound CC(O)O AZHSSKPUVBVXLK-UHFFFAOYSA-N 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000012535 impurity Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
208000021722 neuropathic pain Diseases 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
235000017807 phytochemicals Nutrition 0.000 description 1
229930000223 plant secondary metabolite Natural products 0.000 description 1
229940068918 polyethylene glycol 400 Drugs 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
238000012552 review Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
239000012747 synergistic agent Substances 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA3060909A 2018-09-06 2019-11-05 Procede d'encapsulation de cannabinoides dans des supports de phospholipides Pending CA3060909A1 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201862727996P	2018-09-06	2018-09-06
US62/727,996		2018-09-06
US16/560,470		2019-09-04
US16/560,470 US11020355B2 (en)	2018-09-06	2019-09-04	Method of encapsulating cannabinoids in phospholipid carriers

Publications (1)

Publication Number	Publication Date
CA3060909A1 true CA3060909A1 (fr)	2020-03-06

Family

ID=69718614

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA3060909A Pending CA3060909A1 (fr)	2018-09-06	2019-11-05	Procede d'encapsulation de cannabinoides dans des supports de phospholipides

Country Status (1)

Country	Link
CA (1)	CA3060909A1 (fr)

2019
- 2019-11-05 CA CA3060909A patent/CA3060909A1/fr active Pending

Publication	Publication Date	Title
US20210401766A1 (en)	2021-12-30	Method of Using Cannabinoids Encapsulated in Phospholipid Carriers for Transmucosal and Transdermal Administration
US11020355B2 (en)	2021-06-01	Method of encapsulating cannabinoids in phospholipid carriers
EP3582750B1 (fr)	2023-07-26	Formulations orales de cannabinoïdes
US20210228534A1 (en)	2021-07-29	Self-emulsifying compositions of cannabinoids
US20210251948A1 (en)	2021-08-19	Nanoemulsion hydrophobic substances
US20200345656A1 (en)	2020-11-05	Cannabinoids compositions and methods
US11458092B2 (en)	2022-10-04	Composition with enhanced passenger molecule loading
EP3782602A1 (fr)	2021-02-24	Une composition à chargement de molécules passagers amélioré d'utilisation dans un procédé d'application
US20210093559A1 (en)	2021-04-01	Self-emulsifying anhydrous intradermal depot gel
CA3060909A1 (fr)	2020-03-06	Procede d'encapsulation de cannabinoides dans des supports de phospholipides
CA3060927A1 (fr)	2020-03-06	Formulation derivee du cannabis sativa pour la livraison transfermale et transmuqueuse
US20240316075A1 (en)	2024-09-26	Methods for treatment of pain with cannabinoids
EP4054530A1 (fr)	2022-09-14	Formulation de cannabinoïdes auto-émulsifiante et méthode
US20230355523A1 (en)	2023-11-09	Self-emulsifying nano-emulsions
CN104023717B (zh)	2017-08-04	包括脂质微胶囊递送媒剂的局部调配物和其用途
US20240366633A1 (en)	2024-11-07	Methods for treatment of opioid use disorder with cannabinoids
US20210059935A1 (en)	2021-03-04	Self-emulsifying nano-emulsions
EP3873434A1 (fr)	2021-09-08	Compositions nasales et méthodes